A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention
NCT02066415
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
667
Enrollment
INDUSTRY
Sponsor class
Conditions
Treatment for Prevention of Chronic Migraine
Interventions
BIOLOGICAL:
Erenumab
DRUG:
Placebo
Sponsor
Amgen